Vedere Bio
AcquiredBringing vision back to life.
Cambridge, United States · Founded 2020
- Headquarters
- Cambridge, Massachusetts
- Employees
- 1–10
- Founded
- 2020
- Business Model
- B2B
- Website
- vederebio.com
- Acquired by
- Novartis AGOct 2020 · $150.0M
About
Vedere Bio II, Inc. was a Cambridge, Massachusetts-based biotechnology company developing next-generation ocular gene therapies for vision restoration and preservation in patients with vision loss due to photoreceptor death. Founded in 2020 by leaders of the original Vedere Bio (acquired by Novartis in 2020), the company raised $77M in Series A funding before winding down operations in April 2023.
Summary
Vedere Bio is a Biotech company based in Cambridge, United States, founded in 2020. Investors include Novartis Venture Fund.
Tech & App Stack
4 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Oct 2020
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/vedere-bio"><img src="https://indexed.vc/api/badge/company/vedere-bio" alt="Vedere Bio on Indexed.vc" width="260" height="76" /></a>